The average one-year price target for Medpace Holdings (NASDAQGS:MEDP) (BMV:MEDP) has been revised to $664.95 / share. This is an increase of 11.73% from the prior estimate of $595.15 dated October 20, 2026. These figures represent the aggregate consensus of anal

Medpace Holdings Consensus Price Target Increased by 11.73% to $664.95

Key PointsNet new business awards reached $873 million in the third quarter.

Medpace: 3 Key Takeaways for Long-Term Investors

Medpace Holdings, Inc. reported its financial results for the third quarter ended September 30, 2026, with revenue increasing 8.5% to $716.0 million compared to $659.9 million for the comparable prior-year period. GAAP net income for the quarter was $137.5 million, or $4.84 per d

Medpace Holdings, Inc. Reports Third Quarter 2026 Results and Announces New $1.0 billion Share Repurchase Program

(RTTNews) - Medpace Holdings, Inc. (MEDP) revealed earnings for its third quarter that Increased, from the same period last year

Medpace Holdings, Inc. Profit Climbs In Q3 

Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results this Wednesday after the bell. Here’s what you need to know.

What To Expect From Medpace’s (MEDP) Q3 Earnings

Medpace (MEDP) demonstrates strong technical momentum, maintaining a 100% “Buy” technical opinion from Barchart. Shares are up more than 20% over the past year. Valuation remains a concern, with a trailing P/E of 36.35x. I maintain a “Hold” stance, recommending existing holders use a stop loss due to high volatility...

Don’t Chase Medpace Stock Here Despite Its Strong Technical Momentum

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Medpace Holdings, Inc. News